CTRI/2021/07/034751
Not yet recruiting
Phase 1
Phase 1/2 study of the efficacy 3 mg Peg GCSF in adjuvant and/or neoadjuvant dose dense breast cancer treatment protocols.
Abhishek Pathak0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Health Condition 1: C501- Malignant neoplasm of central portion of breast
- Sponsor
- Abhishek Pathak
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed female patients with invasive ductal carcinoma breast requiring neoadjuvant or adjuvant dd\-AC/EC protocol.
Exclusion Criteria
- •1\.Previous exposure to chemotherapy or radiotherapy.
- •2\.Patients suffering from other causes of myelosuppression (aplastic anemia, drug related, viral infection)
- •3\.HbsAg or anti HCV positive patients.
- •4\.Uncontrolled diabetes mellitus, HbA1C \> 7\.5 g%
- •5\.History of severe Covid in last 06 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A single arm phase 2 study on the efficacy of Pegfilgrastim (Neulasta) after DCEP chemotherapy: a feasibility study in multiple myeloma patients eligible for autologous transplant. - NDmultiple myelomaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000103-29-ITOSPEDALE POLICLINICO S. MATTEO
Recruiting
Phase 2
A Phase2 study of the safety and efficacy of pegfilgrastism for the prevention of febrile neutropenia in patients receiving TPF therapy for squamous cell carcinoma of the head and neck.JPRN-jRCTs031220695Saito Yuki18
Completed
Not Applicable
G-CSF in treatment of premature neonates with neutropenia and clinical sepsisneonatal sepsis.Other infectious diseasesIRCT201303252639N11Deputy for research of Shahid Sadoughi University of Medical Sciences , Yazd, Iran .40
Active, not recruiting
Phase 3
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After ChemotherapyNeutropenia, Chemotherapy-Induced FebrileBreast Neoplasm FemaleNCT06711523Kexing Biopharm Co., Ltd.250
Unknown
Phase 2
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced NeutropeniaNeutropeniaNCT01918241Hangzhou Jiuyuan Gene Engineering Co. Ltd.,200